Cue Biopharma, Inc. (CUE): Cash & Equivalents
$27.14M
As of 2025-12-31
$17.39M
As of 2026-06-30
-19.3%
3-year compound annual growth
-18.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.14M | +20.8% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $22.46M | -53.7% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $48.51M | -6.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $51.61M | -19.8% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $64.37M | -14.0% | 2023-03-21, Balance as of period end |
| 2020-12-31 | $74.87M | +69.0% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $44.29M | +112.9% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $20.80M | n/a | 2020-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.14M | +20.8% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $204.99M | +130.8% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $9.02M | +28.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $23.02M | +863.4% |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗